BRIEF published on 03/05/2024 at 10:05, 8 months 16 days ago Nabaltec AG Achieves 9.1% EBIT Margin in 2023 Despite Economic Challenges, Expects Growth in 2024 EBIT Margin Nabaltec AG Economic Demand 2024 Growth Expectation Chemical Industry
PRESS RELEASE published on 03/05/2024 at 10:00, 8 months 16 days ago Nabaltec AG achieves an EBIT margin of 9.1% in 2023 despite weak economic demand and expects slight growth in 2024 Nabaltec AG achieves 9.1% EBIT margin in 2023 despite weak economic demand & expects slight growth in 2024. Revenues down 8.5% but above industry average Revenue EBIT Margin Nabaltec AG Economic Demand Industry Performance
PRESS RELEASE published on 11/28/2023 at 10:00, 11 months 23 days ago EQS-News: Nabaltec AG expands cooperation with OTH Amberg-Weiden
PRESS RELEASE published on 08/24/2023 at 10:00, 1 year 2 months ago Nabaltec AG publishes half-year report 2023
PRESS RELEASE published on 08/04/2023 at 11:35, 1 year 3 months ago EQS-Adhoc: Nabaltec lowers forecast for Financial Year 2023
PRESS RELEASE published on 07/25/2023 at 18:15, 1 year 3 months ago Nabaltec AG receives Bavaria's Best 50 award
PRESS RELEASE published on 06/28/2023 at 13:54, 1 year 4 months ago Nabaltec AG: Shareholders adopt dividend in the amount of EUR 0.28 per share
PRESS RELEASE published on 05/26/2023 at 10:00, 1 year 5 months ago Nabaltec AG again honored with the Best Managed Companies Award
PRESS RELEASE published on 05/25/2023 at 10:00, 1 year 5 months ago Nabaltec AG achieves revenue growth of 4% to EUR 57.0 million in the first three months of 2023
PRESS RELEASE published on 04/27/2023 at 10:00, 1 year 6 months ago Nabaltec AG achieves record figures once again in Financial Year 2022 as well as revenues of EUR 57 million in the first quarter of 2023 according to preliminary figures
Published on 11/21/2024 at 22:05, 1 hour 28 minutes ago Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 1 hour 43 minutes ago Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 3 hours 18 minutes ago Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 3 hours 23 minutes ago For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform
Published on 11/21/2024 at 20:00, 3 hours 33 minutes ago Victory for New York Homeowners: Petroff Amshen LLP Blocks Lender’s Repeated Foreclosure Attempt
Published on 11/21/2024 at 19:01, 4 hours 32 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/21/2024 at 18:36, 4 hours 57 minutes ago Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 5 hours 34 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 5 hours 41 minutes ago LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 5 hours 41 minutes ago 2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.
Published on 11/21/2024 at 06:58, 16 hours 35 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 4 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 5 hours ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 5 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 15 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
